Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03995368 · ClinicalTrials.gov registry record · NA

Neuroplasticity in TBI and Schizophrenia

A NA study, sponsored by VA Office of Research and Development.

Completed
Registry status
NA
Development phase
93
Enrollment target

NCT03995368: Completed NA study, sponsored by VA Office of Research and Development.

NCT03995368 is a NA study that has completed, run by VA Office of Research and Development. The registered enrollment target is 93 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03995368, a NA study, has completed, sponsored by VA Office of Research and Development.

COMPLETED
Registry status
NA
Development phase
93 participants
Enrollment target

Study Summary

This proposal will examine measures of neuroplasticity (the brain's ability to alter its function or structure in response to changes in the environment or novel experiences) in Veterans with schizophrenia or traumatic brain injury (TBI). Both conditions are associated with impaired cognition (for example, attention, memory, learning), which is in turn associated with poor community functioning and integration. However, the two disorders differ in their origins: schizophrenia is a neurodevelopmental disorder appearing usually in late adolescence while TBI is an acquired disorder as the result of an injury to the head. Understanding of the root causes of complex cognitive impairments associated with these disorders remains limited. Neuroplasticity is a fundamental brain process that underlies cognitive functioning and may give insight into the causes of cognitive dysfunction in TBI and schizophrenia. Neuroplasticity will be measured using electroencephalography (EEG) by placing small electrodes on the scalp that record the brain's electrical activity. Participants will listen to simple auditory tones and view simple visual patterns while their EEG is recorded. Additionally, participants will have measures of cognition and clinical interviews for diagnosis of a disorder as well as any current levels of symptoms.

Primary Outcome

Electroencephalography (EEG) measures the brain's activity while viewing simple visual stimuli or listening to simple auditory tones. MMN is measured while listening to a series of auditory tones, and is derived as the difference in responses to common stimuli minus rare stimuli (e.g., stimuli presented 90% of the time minus stimuli presented 10% of the time). A more negative value indicates stronger MMN, a more positive value indicates a stronger Repetition Positivity (RP) to the Standard stimu

Interventions

  • OTHER Electroencephalography

Trial Details

FieldValue
Enrollment Target 93 participants
Start Date 2020-11-09
Est. Completion 2023-04-19
Phase NA
VA Office of Research and Development

1,668 total trials

What the finished NCT03995368 record still lists

NCT03995368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 93 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (93% lower).

The record links to 0 conditions, and to 1 intervention - of which Electroencephalography is the first listed.

NCT03995368 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03995368 about?

NCT03995368 is a clinical study titled "Neuroplasticity in TBI and Schizophrenia". This proposal will examine measures of neuroplasticity (the brain's ability to alter its function or structure in response to changes in the environment or novel experiences) in Veterans with schizophrenia or traumatic brain injury (TBI). Both conditions are associated with impaired cognition (for e...

What is the current status of trial NCT03995368?

This trial is currently completed. It is a NA study. The enrollment target is 93 participants. The study started on 2020-11-09. Estimated completion is 2023-04-19.

What interventions are being tested in trial NCT03995368?

The interventions under investigation include: Electroencephalography (OTHER).

Who is sponsoring clinical trial NCT03995368?

This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03995368's enrollment target sits among peer trials

93 937th of 2000 higher than 1,064 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02203526 · 93 participants · Phase 1

    Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma

  • NCT03089554 · 93 participants · Phase 2

    Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

  • NCT05000021 · 93 participants · NA

    Reducing Diabetes Distress Using Cognitive Behavioral Therapy in Young Adults With Type 1 Diabetes

  • NCT05489887 · 93 participants · Phase 2

    Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03995368, the US trial registry maintained by the National Library of Medicine. NCT03995368 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.